multiple sclerosis Archives -

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral

Supreme court throws Novartis a lifeline for Gilenya defense

https://pharmaphorum.com/news/supreme-court-throws-novartis-a-lifeline-for-gilenya-defense/

News/ News/ Sales and Marketing

Whistleblower gets $250m as Biogen settles US kickbacks case

Phil Taylor Avonex, Biogen, litigation, multiple sclerosis, Tecfidera, Tysabri, US 0 Comment

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to

Whistleblower gets $250m as Biogen settles US kickbacks case

https://pharmaphorum.com/news/whistleblower-gets-250m-as-biogen-settles-us-kickbacks-case/

News/ News/ Sales and Marketing

Novartis knocked back again in bid to block Gilenya generics in US

Phil Taylor Gilenya, HEC Pharma, litigation, multiple sclerosis, Novartis, patent 0 Comment

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early

Novartis knocked back again in bid to block Gilenya generics in US

https://pharmaphorum.com/news/novartis-knocked-back-again-in-bid-to-block-gilenya-generics-in-us/

xray image of human head with brain and electric pulses

News/ News/ R&D

Sanofi pauses enrolment in ex-US tolebrutinib trials

Phil Taylor BTK inhibitor, evobrutinib, Merck KGaA, multiple sclerosis, safety, Sanofi 0 Comment

Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although

Sanofi pauses enrolment in ex-US tolebrutinib trials

https://pharmaphorum.com/news/sanofi-pauses-enrolment-in-ex-us-tolebrutinib-trials/

News/ News/ R&D

Liver injuries prompt clinical hold on Sanofi BTK drug

Phil Taylor Biogen, BTK inhibitor, Merck KGaA, multiple sclerosis, myasthenia gravis, Roche, safety, Sanofi 0 Comment

One of the main assets of Sanofi’s $3.7 billion buyout of Principia Biopharma has run into trouble, after

Liver injuries prompt clinical hold on Sanofi BTK drug

https://pharmaphorum.com/news/liver-injuries-prompt-clinical-hold-on-sanofi-btk-drug/

News/ News/ Sales and Marketing

Novartis faces threat of early generic of MS drug Gilenya in US

Phil Taylor generics, multiple sclerosis, Novartis, patent litigation 0 Comment

Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after

Novartis faces threat of early generic of MS drug Gilenya in US

https://pharmaphorum.com/news/novartis-faces-threat-of-early-generic-of-ms-drug-gilenya-in-us/

Digital/ News/ News

Biogen grabs MS music therapy from MedRhythms in $120m deal

Phil Taylor Biogen, digital, digital health, digital therapeutics, MedRhythms, multiple sclerosis, Music, neurology 0 Comment

Biogen has licensed rights to a digital therapeutic (DTx) developed by MedRhythms which combines sensors, software, and music

Biogen grabs MS music therapy from MedRhythms in $120m deal

https://pharmaphorum.com/news/biogen-grabs-ms-music-therapy-from-medrhythms-in-120m-deal/

Market Access/ News/ News/ News/ Patients

NICE backs Biogen’s Vumerity for multiple sclerosis

Phil Taylor access, Biogen, multiple sclerosis, neurology, NHS, NICE, Tecfidera, Vumerity 0 Comment

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen’s

NICE backs Biogen’s Vumerity for multiple sclerosis

https://pharmaphorum.com/news/nice-backs-biogens-vumerity-for-multiple-sclerosis/

News/ News/ Sales and Marketing

Novartis blocks generic to MS blockbuster Gilenya in US patent dispute

Phil Taylor Gilenya, HEC Pharma, multiple sclerosis, Novartis, patent litigation 0 Comment

Novartis has blocked an attempt by Chinese drugmaker HEC Pharma to launch a generic version of its big-selling

Novartis blocks generic to MS blockbuster Gilenya in US patent dispute

https://pharmaphorum.com/news/novartis-defends-ms-blockbuster-gilenya-in-patent-dispute/

Trending

multiple sclerosis

Login